Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 23, 2020

LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia

LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1 clinical trial.

LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia